Swiss Identity

More

Novartis buys vaccine maker Chiron

This content was published on Oct 31, 2005 Novartis, which plans to revamp Chiron, says the acquisition provides it with growth platforms in the vaccines market and in the molecular diagnostic business. The Basel-based company, which already owns 42 per cent of the shares in Chiron, increased its bid for the remaining 58 per cent to $45 a share, it was announced on…